.jpg)
SIR 2025
Interventional Oncology
Traditional Poster
Qian Yu, MD (he/him/his)
Resident
University of Chicago, United States
Wali Badar, MD
Resident physician
University of Illinois at Chicago, United States
Mikin V. Patel, MD
Assistant Professor of Radiology
Department of Radiology, University of Chicago, United States
Aaron W. Lyon, MD
Medical Student
University of Washington, United States
Daniel Kwak, MD, PhD
Radiology Resident
University of Chicago, United States
Yousuf Islam, None
student
University of Chicago, United States
Zheng Feng Lu, PhD
Professor
University of Chicago, United States
Thuong G. Van Ha, MD, FSIR
Professor
The University of Chicago, United States
Osman Ahmed, MD, FSIR
Associate Professor of Radiology
University of Chicago, United States
The effectiveness of percutaneous thermoablation for treatment of liver metastases greater than 3cm can be limited by the ability to achieve adequate ablation coverage. Radiation segmentectomy (RS) has been proven effective for treatment of hepatocellular carcinoma up to 8cm. This study aims to assess the safety and effectiveness of RS for treatment of secondary liver tumors >3cm. A total of 25 secondary liver tumors (mean diameter: 4.7 ± 1.5cm; single hepatic lesion: 28%[7/25]) in 24 patients (mean age: 64.5 ± 16.9, M:F=14:10), including 13 colorectal cancer, 2 renal cell carcinoma, 2 uveal melanoma, 2 pancreatic carcinoma, 2 adenoid cystic carcinoma, 1 endometrial carcinoma, 1 prostate cancer, 1 neuroendocrine tumor, and 1 tonsillar adenocarcinoma. The mean segmentectomy dose was 342.6 ± 122.6Gy; eight patients also received additional lobar treatments (33.3%). RR and DCR were 56% (14/25) and 68% (17/25), respectively. The 1-yr and 3-yr response rates were 48.6% and 30.4%, respectively, with a median PFS of 8.8 months (95%CI: 9.5-not reached). The 1-yr and 3-yr OS were 79.4% and 24.8%, respectively, with a median OS of 24.4 months (95%CI: 20.6-not reached).One patient (4.2%) developed grade 3 thrombocytopenia, requiring holding of systemic treatment. No additional grade 3 or above adverse events occurred. RS is a feasible treatment option for secondary liver tumors >3cm with few major adverse events.
Materials and Methods: A retrospectively review at a single institution was performed from December 2017 to February 2024 to include patients treated with RS for liver metastases using glass microspheres. RS was defined as a target dose >200Gy to no more than two liver segments. The following outcomes were retrieved: overall survival (OS), target tumor response, target tumor progression-free survival (PFS), and 3-month serum toxicity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. The best radiologic response rate (RR) and disease control rate (DCR) were assessed according to RECIST 1.1 criteria.
Results:
Conclusion: